Understanding primary aldosteronism in patients from Western Norway

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify and include patients diagnosed with primary aldosteronism (PA) in Western and Mid-Norway. It focuses on describing patient characteristics, exploring cardiac effects of PA before and after treatment, and assessing long-term outcomes. Subgroups of patients will undergo echocardiography and cardiac MRI to evaluate myocardial function and structure, with comparisons made to healthy controls. The study also aims to create a national registry of PA patients diagnosed or subtyped with adrenal vein sampling at Oslo University Hospital starting in 2025.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Verified diagnosis or strong suspicion of primary aldosteronism
* Age 18-85

Exclusion Criteria:

* Active cancer disease at time of inclusion

Exclusion criteria for subgroup of primary aldosteronism-patients and healthy controls who perform cardiac MRI:

* Asthma/chronic obstructive pulmonary disease ,
* Use of dipyridamole
* Claustrophobia

Where it's running

• Haukeland University Hospital
  Bergen, Norway Recruiting
• Oslo University Hospital
  Oslo, Norway Not yet recruiting

Study contacts

• Principal investigator: Marianne A Grytaas, MD PhD — Haukeland University Hospital
• Study coordinator: Marianne A Grytaas, MD PhD
• Email: marianne.grytaas@helse-bergen.no
• Phone: +4741545435

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adrenal Diseases in Modena: A Patient Registry at Modena University Hospital

  This study collects medical histories and treatment data from patients with adrenal diseases to see how they are diagnosed and managed in Modena.

  Recruiting Azienda Ospedaliero-Universitaria di Modena · Modena, Modena · NCT07920198

• Targeted adrenal artery embolization versus oral spironolactone for idiopathic hyperaldosteronism

  This trial will test whether a minimally invasive targeted adrenal artery embolization works as well as the oral drug spironolactone for people aged 15–60 with idiopathic hyperaldosteronism.

  Recruiting at 3 sites Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07328230

• Aldosterone-hybrid test to guide curable treatment for primary aldosteronism

  This trial tests whether non-invasive biomarkers plus CT imaging can identify unilateral primary aldosteronism and reduce the need for adrenal vein sampling in patients considered for surgery.

  Recruiting at 4 sites Changi General Hospital · Singapore, Singapore and 5 other locations · NCT07297745

• Adrenal vein sampling in China

  This project tests whether different adrenal venous sampling techniques and AVS-guided management help people with primary aldosteronism get better long-term blood pressure and hormone results.

  Recruiting at 76 sites Chinese Academy of Medical Sciences, Fuwai Hospital · Hefei, Anhui and 75 other locations · NCT07252284

• Evaluating adrenal gland function using a new imaging agent in patients with hormone-related conditions

  This study is testing a new imaging agent to see if it can help find adrenal tumors in adults with hormone-related conditions like hyperaldosteronism or hypercortisolism.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06246357

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.